SCHEMBL1383225

SCHEMBL1383225

O=CNN1CCc2ccccc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.44
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
USP2 O75604 1/20 0.44
CDK4 P11802 1/20 0.44
ALOX15 P16050 1/20 0.44
CCND1 P24385 1/20 0.44
NOTUM Q6P988 1/20 0.43
TSHR P16473 2/20 0.42
SIGMAR1 Q99720 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.41
NPC1 O15118 2/20 0.41
PKM P14618 2/20 0.41
NFKB1 P19838 2/20 0.41
RAB9A P51151 2/20 0.41
NFKB2 Q00653 2/20 0.41
RELA Q04206 2/20 0.41
TP53 P04637 1/20 0.41
HPGD P15428 1/20 0.41
MAPT P10636 4/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9038764 0.89 SMN1; SMN2 (0.49) ALDH1A1MEN1KMT2ANOTUMTSHR
SCHEMBL8979214 0.75 ALDH1A1 (0.48) ALDH1A1MEN1KMT2AUSP2CDK4
SCHEMBL5698473 0.75 ALDH1A1 (0.48) ALDH1A1MEN1KMT2AUSP2CDK4
SCHEMBL27564281 0.74 ALDH1A1 (0.44) ALDH1A1MEN1KMT2AUSP2CDK4
SCHEMBL5120536 0.73 NOTUM (0.50) ALDH1A1MEN1KMT2ANOTUMTSHR
SCHEMBL7126729 0.73 ALDH1A1 (0.51) ALDH1A1MEN1KMT2ANOTUMTSHR
SCHEMBL29985725 0.73 ALDH1A1 (0.51) ALDH1A1MEN1KMT2ANOTUMTSHR
SCHEMBL307373 0.73 TSHR (0.45) ALDH1A1MEN1KMT2ANOTUMTSHR
SCHEMBL28654768 0.73 SMN1; SMN2 (0.46) ALDH1A1MEN1KMT2ANOTUMTSHR
SCHEMBL2203263 0.72 NPC1 (0.50) ALDH1A1MEN1KMT2AUSP2CDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105518005-B Tricyclic pyridine-carboxamide derivatives as ROCK inhibitors 百时美施贵宝公司 2018-07-20 CN claimed
CN-105073741-B Phthalazinones and isoquinolinones as ROCK inhibitors 百时美施贵宝公司 2017-08-08 CN claimed
CN-104540806-B Azaheterocycles as BIR2 and/or BIR3 inhibitors 霍夫曼-拉罗奇有限公司 2017-05-03 CN claimed
CN-102725292-A Imidazopyridine compounds as novel constructs for multi-target kinase inhibition ABBOTT LAB 2012-10-10 CN claimed
JP-4838934-B2 2011-12-14 JP claimed
EP-1042291-A1 ARYL-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS Klinge Pharma GmbH (DE) 2000-10-11 EP claimed
WO-1999031064-A1 ARYL-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS KLINGE PHARMA GMBH (DE) 1999-06-24 WO claimed
US-12391666-B2 Indoline-1-formamide compound, preparation method therefor, and medical use thereof BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) 2025-08-19 US disclosed
CN-112384506-B Indoline-1-formamide compound, preparation method and application thereof in medicine and pharmacology 北京诺诚健华医药科技有限公司 2023-01-24 CN disclosed
CN-112384506-B Indoline-1-formamide compound, preparation method and application thereof in medicine and pharmacology 北京诺诚健华医药科技有限公司 2023-01-24 CN disclosed
CN-112384506-B Indoline-1-formamide compound, preparation method and application thereof in medicine and pharmacology 北京诺诚健华医药科技有限公司 2023-01-24 CN disclosed
CN-112384506-A Indoline-1-formamide compound, preparation method and application thereof in medicine and pharmacology 北京诺诚健华医药科技有限公司 2021-02-19 CN disclosed
CN-112384506-A Indoline-1-formamide compound, preparation method and application thereof in medicine and pharmacology 北京诺诚健华医药科技有限公司 2021-02-19 CN disclosed
CN-105073741-B Phthalazinones and isoquinolinones as ROCK inhibitors 百时美施贵宝公司 2017-08-08 CN disclosed
CN-106817899-A Spiroheptane as ROCK inhibitor 百时美施贵宝公司 2017-06-09 CN disclosed
CN-102725292-A Imidazopyridine compounds as novel constructs for multi-target kinase inhibition ABBOTT LAB 2012-10-10 CN disclosed
US-7320993-B1 Aryl-substituted pyridylalkane, alkene, and alkine carboxamides useful as cytostatic useful as cytostatic and immuosuppressive agents ASTELLAS DEUTSCHLAND GMBH (DE) 2008-01-22 US disclosed
CN-1658759-A Insecticidal amides with nitrogen-containing benzo-fused bicyclic ring systems DU PONT (US) 2005-08-24 CN disclosed
US-4619784-A XANTHENE DERIVATIVES POLAROID CORPORATION, PATENT DEPT. (US) 1986-10-28 US disclosed
US-4267251-A DIFFUSION TRANSFER POLAROID CORPORATION (US) 1981-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12391666-B2 Indoline-1-formamide compound, preparation method therefor, and medical use thereof FLT1, KDR, TEK ALDH1A1 783/4885MEN1 342/4885KMT2A 1659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.